These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39427300)

  • 1. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
    Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
    J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Loft JA; Riis PT; Schultz NA; Bjerrum S; Schønning K; Pedersen CR; Krohn PS; Nielsen SD
    Ugeskr Laeger; 2024 Apr; 186(15):. PubMed ID: 38708697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
    Royston L; Papanicolaou GA; Neofytos D
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
    Monday LM; Keri V; Chandrasekar PH
    Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.
    Strasfeld L; Lee I; Tatarowicz W; Villano S; Chou S
    J Infect Dis; 2010 Jul; 202(1):104-8. PubMed ID: 20504236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
    Winston DJ; Saliba F; Blumberg E; Abouljoud M; Garcia-Diaz JB; Goss JA; Clough L; Avery R; Limaye AP; Ericzon BG; Navasa M; Troisi RI; Chen H; Villano SA; Uknis ME;
    Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB; Pouch SM; Phadke VK; Karadkhele G; Larsen CP; Woodworth MH
    Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
    Vinuesa V; Bracho MA; Albert E; Solano C; Torres-Puente M; Giménez E; González-Candelas F; Navarro D
    J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.